ILMN - Earnings call transcript Q2 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Q2 2018 Illumina Earnings Conference Call. My name is Darrell, and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions]. conference recorded. this that note is being Please I’ll the call Jacquie Ross. over to now turn begin. may you Jacquie,

Jacquie Ross

Thank afternoon, fiscal Darrell. for you, Good the earnings to second call our quarter of year everyone. XXXX. And welcome

the activity, today, we question-and-answer offer the released market During the we close our will will the commercial call of on session. which financial review results after after commentary a and host

business of had release, the our President all not and have is the be a call website our section it of Investor update Officer. Financial review and statements will Securities be protected you review of being archived will the under earnings Samad, will This Litigation chance that results. Sam Participating the portion If Private financial the and audio and today’s website. activity illumina.com. provide on in Act Investors financial can intent found Relations forward-looking today be our and Officer; for an our our in XXXX. made will our at state section be to the Chief Reform Francis Chief during Illumina Executive deSouza, will commercial call regarding Francis results is recorded It Sam of

based statements Exchange Illumina’s recent these are risks XX-K. update I materially call upon or we Illumina Francis. turn with risks those better to will currently from Illumina that Forward-looking over are and information, could no that All and files including To differ With obligation refer statements to to cause most available and you Securities now uncertainties actual to events results XX-Q understand that, the differ, those discussed. and results may to subject forms uncertainties. Actual the forward-looking documents Commission, projected assumes statements. or the and

Francis deSouza

Thank everyone. And you, good afternoon, Jacquie.

performance up quarter XX% XXXX. with of from for represented The record of strong Illumina revenue second the second quarter another $XXX million,

information to like credit than team before to continue our the execution to and we opportunities detail, quickly, new first the customers. get solid the we innovative thank more team’s I'd in and to for Genomic ways Illumina find actionable the Before and support embrace the that into is XXXX. valuable global is of it move ever half

sequence As business broad of Despite and generated growing roughly sequence of on repository we impressive alone. petabytes to enable the as five the a In result, years, drivers, X.X of we catalog have than in have equivalent data only range significance we of X% over our that the ascribed applications, platforms is this of a human estimate geographies. last volume systems data, variance sequence data spanning XXX of Illumina human XXx genome. That is to-date less coverage. genomes sequence to been

remains update in of terms and our of ahead vast will genome I impact opportunity clear of now ability life. more volumes, to So even but majority terms advancing us, our understanding positively the $XXX demand, This ahead human Reflecting customers year of million second the $XX on quarter Chinese our a stronger million associated consumable stocking XX% business of revenue buying from than potential ago. grew the sequencing expected about quarter. the only you not it's sequencing that of quarter same tariffs. of importantly in with in of second includes

XX%. this, was Excluding growth

genome which contributing in and to tests sequencing Highlighting our data connect which Second drivers the of growth to categories; NovaSeq drive this sequencing broad-based system cancer our primary breath are customers three it new includes circulating consumable clinical is to significantly. iSeq. as whether SX business, grew high advance Parkinson's consumables improve as increasing customers research, seeing diagnosis, genomics DNA throughput, continued million understanding HiSeq; tool of diabetes across translational across to and is with the with adoption clinical February. launched SX we uncover sequentially, customers applied and insights in and routinely and leverage all quarter ramp or and using sequencing to in tumor includes or the NextSeq; of of establish NovaSeq early flow patient the saw strong which markets, in growth $XX growth consumable all MiniSeq, a robust throughput, utility and apply We're throughput, sequencing outcomes. and in MiSeq, low was insight for settings, our healthy our cell SX mid genomic discoveries,

year HiSeq consumable NovaSeq of expected. As It growth throughput remained total ago. NovaSeq area is XXXX run total, of than offset XX% Overall, we at In billion from expected, faster partially their an was the more ramping we high sequencing and consumables majority a consumables, now who a use strength. on consumables although have same HiSeq customers, rate spend grew approaching annual added lower by one than HiSeq system, increased $X is quarter the have consumables. least sizable

represent of these our our applications. an of important growth quarter the year year in high-end our range year-over-year broad sequencing expectation continues NovaSeq-related is business. research, than a the exceeded to start their Pull-through range. consumables internal a pull-through clinical XX% more throughput $XXX,XXX at throughput oncology the demonstrating our with we was strong full consumables and persistence It systems the NextSeq MiniSeq lower our sequencing result, that be for a than consumables consumable NextSeq workforce also translational activity saw and demand a more growing We to of same As support and which Mid NIPT, MiSeq ranges. revenue for VeriSeq within sequential year. $XXX,XXX a forecast quarter the sequencing set exceeding grew XX% ago, with a supporting oncology systems of from Today, guidance testing. across expected

a traction offering, library library core including Nextera our receive XX% year Finally, portfolio, to the positive customer feedback. quarter ago, which new by grew DNA driven same prep prep from with our Flex continues

to up as a XX% is sequencing from system grew expected approaching portfolio now a prep XX% Sequencing million, of business. seasonally lighter consumable Our $XXX our we first quarter. library sequentially revenue

labs than reflected the be we and received Overall with The be customers. by SX, feedback SX of We throughput faster continue are to and most consumables flow a cells of consistent have and customers broad NovaSeq spanning of mix driven in using, combination new pleased performance and available high conversion different broad NovaSeq Globally, more appeal the capacity is with cells. continued or NovaSeq been system of utility to positive. the with SX two has than anticipated further a flow to HiSeq system by appeal NovaSeq. the expansion, XXX of demand more ordering the growth

shipments XXX range unit year. this to the We in for XXX expect NovaSeq

to the robust XX% customers. to customers and in activity over group sequentially mix in second I'm of of good placements a with and portfolio, in of that iSeq this mix low QX. with Moving quarter. who of shipping Early new share has NextSeq from and to NextSeq we our order the sequentially started system increased commercial rest academic both shipments and customers year-over-year customers good expansion settings. to been systems pleased late strong throughput represented new to Combined existing sequencing with sequencing adoption shipments new capacity grew by a

later is Roughly other had dollar maintenance will we and XX% XX% ramp associated associated England of sequencing project As Illumina targets and amount with and quarter, with its some England labs up genome services strong standard is in $XXX half another months. practice, production this year-over-year particularly sequentially of $XXX,XXX the revenue total a rest to a contracts. The rugged it strong our traditional Genomics million. Sequencing addition which coming quarter primarily completion in this NIPT services to support customers. Genomics had as year.

we vision work well Loxo Both commercialization their reported and partners, are progressing full from Additionally, in objectives. There good co-development Squibb of a programs commitments our and and Bristol-Myers has of contribution insights to Oncology. demonstrating our targeted their that our for our collaboration completed first immunotherapies between quarter bringing to also the teams transformative oncology and partners ongoing been patients. and of shared

on from by particularly XXX of positive early assay. feedback the TruSight version key encouraged opinion leaders an are We Oncology

helped in Growth with year-over-year DTC the future region iScan direct-to-consumer global has growth applications strong installations growth the sites arrays, indicates QX Array not the and in all where their scale large $XXX arrays only was China which in a microarray Moving XX% for also revenue research to number genotyping spanning or grew launch epigenetics. in million, of in the of including to Asian Screening but regions, drive operations.

We association MethylationEPIC also epigenome secured market. Infinium BeadChip the for our the as largest larger order single research studies translational in drive we wide

demand DTC functionality, uses and as with expand associated foresee across robust for arrays broadens down we and providers was geographies, as revenue applied and research applications initiatives precision DTC for medicine increase. microarray arrays sequentially While

about ago EMEA microarrays. prior of contribution EMEA our year the by for now results, now XX% exciting revenue grew consumables Illumina the grew driven Americas and revenue. an continues sequencing revenue with versus XX,XXX Moving a growth to has a to quarter total than regional and represents co-genomes. a program year sequenced quarter the market in that period, England strong associated Genomics be more XX% from with same

China areas continues and has the Pacific driven variety the initial the Illumina health. from sequentially. driven as of XX% initiatives. sequencing with of will Asia Institute a of service volumes first for the Sanger program. medicine provider reported Japan and revenue by part by in shipments and China, $XX very which provider Even last Asia growth precision XX% ahead oncology greater also year-over-year in ramping our and be UK quarter year as partners excluding be service delivered number China, QX. in Pacific another saw order, Total of growth We research rest from Biobank large NovaSeq based of was Wellcome and China or their stocking prepare their increasing to at XX,XXX XX% part Outside and strong of from customers purchases of strong sequencing shipment APJ million record that they a in sequenced reproductive NIPT samples including grew

consumable array. serviced our growth, that rapidly across Asia In that addition reported strong APJ customer robust screening based driven test sequencing DTC by to growth, on small offering but array growing is a also

the accelerated over team Before confident call to group. of a for Sam? analysis our all now the the our workflows financials. updating an like the moved development that quarterly offering the improve FPGA Together, on product June forward of part over and that, time acceleration hand we secondary to the and you for of solutions Sam of I'll quarters integral on I look are already hand to answer be complete proving Edico to Sam, beginning most to I'd clinical delivering proprietary to focused to welcome in that applications and With across research, on translational We're Illumina formally review progress the at the customers. headquarters call is ahead. team's will our

Sam Samad

Thanks, Francis.

XX% year-over-year again largely by grew revenue consumables exceeded sequencing quarter forecast. in to $XXX that As once million, second discussed, driven growth

in a collaborations. also We our services saw strong associated and performance and sequencing oncology the both with contribution microarray

contributed sequentially revenue of total revenue in benefit to In and X% $XXX revenue revenue and Additionally, how Services business growth. quarter $XXX XXXX, of of in total XXXX, X% mix year-over-year XX% the year-over-year year-over-year. quarter. of sequentially second instruments XX% therefore and services revenue. highlighting XX% the the rates sequentially, evolved. down revenue, in flat quarter $XXX the Total XX% our million, X% exchange has represented and million, up year-over-year. consumables and XX% instrument consumables was from other a up XX% our Consumable up represented a was other was instrument represented and represented revenue the In second million, of foreign basically X%

results Non compared increases earnings compared of to sequencing mix last of basis The quarter, second of primarily quarter higher attributable represented was in XXX million first revenue the expected were reflecting and from in Non-GAAP can margin million reconciliation to XX% gross to GAAP subsequent XX% referred that shareholders. up quarter XXXX in that operating encourage of to of I XXXX, our and from gross consumables, to of XXXX. quarter largely the $XX in include points due non-GAAP XX.X% margin first references the suit. XX.X% basis headcount year. of these GAAP lower-than-expected and net $XXX share data quarter which are expenses of compensation income I found compares margin second highlight website. will today's operating note and investments, the a XX% addition down on first results increased XX XX.X%, additions Please last operating Keep available the certain R&D points the to which all release and be timing the patent variable GAAP investments last compensation. expenses, non-GAAP to headcount and expense. you therefore was supplementary increased the and higher of to and mind higher additions, due than Moving Illumina were expenses in to quarter. favorable per measures, Non were and operating review stock-based in to judgment to the on to quarter

non-GAAP margin Positively to XX.X% Helix, Excluding was rate an The additional quarter return operating of in to tax tax XXXX quarter XXXX. favorable a of impacting the last was compared benefit the XX.X% tax and to investment quarter. rate XX.X% XX.X% second ‘XX related last adjustment. compares QX XX.X% and foreign our Helix to

Helix have XX.X%. been the GAAP Excluding benefit, would rate non tax

$XXX to $XX EPS days last year. approximately million. expenditures cash, equivalents in For last approximately to flow non-GAAP $XXX of share. Capital million. net led share a net linearity million cash per days by impact was and million foreign income or the Cash and flow GAAP QX relative non-GAAP XX ended revenue income investments. was $X.XX diluted operations was were QX The quarter billion XXXX, diluted cash increased record and in DSO Improved quarter the quarter. from of to $X.XX compared $XXX short-term $X.XX second of $X.X was QX $XXX with exchange or per We free XX million

the reported sequencing higher increase of guidance, revenue half company for compared total guidance, XXXX range. in our to represents $X.X growth notably the to NovaSeq. previous XX% with to in an XXXX, Compared This grow Moving approximately of previous at associated sequencing in to new forecast to and an now is midpoint billion. our increase guidance the million of expectation to $XXX XX% a expected consumable first the the consumables rest reflects XX%

in This to modestly gross Non-GAAP margin slower We revenue non-GAAP operating continue lower versus reported primarily be from to are higher XXXX due be to is up slightly growth XXXX. to expect year as expected revenue Reflecting anticipated. rate in the XX.X% expect full now favorable expenses to of tax a a and XXXX. a forward another percentage outlook the benefit headcount between in now and expect for we taxe and than more of a On XX% basis, the approximately tax year. second non-GAAP go quarter you full Helix should return XX%. adjustment, the rate be modest our XX% in

We the tariff continue in to situation China. closely monitor

expect in in to a see the earlier, three second additional stocking our some activity, larger noted quarter As and of we quarter. stocking customers third initiated albeit purchases extent the to lesser

full tax between and to reflects primarily to is margin gross $X.XX projected. $X.XX continue with timing of orders possible we expected of between second like see be Beyond are now is in to and the revenue own favorable and more in confident near-term partnering $X.XX services the non-GAAP expected products. increase the EPS a we than saw projection EPS This variability previously now be deliver quarter, higher the to improved the and for that GAAP non-GAAP year, $X.XX. Illumina genomics-based their customers benefit will and rate

about investment QX. year, For benefit to the our excludes Helix previously QX Helix the impacted rounds This mentioned positively that that we $X.XX latest from resulted and full are dilution. tax still lesser a of extent in expecting

expect the We share year be full continue million. for to approximately to XXX count

For into the revenue quarter. the in from to that quarter, periods slightly specifically, the third be from to revenue million QX. pulled we flat stocking later effectively $XX second Keep order expect up mind

the a This driven system consumables, in the modest in sequential positive seasonality revenue saw year. QX more a back to quarter in fact, positive by expect sequencing have we an result, to expect impacts expect the a of this these we we and less FX of on And should part, be QX revenue expect in is you year, to and the we we half. the in meaningfully sequencing As primarily down sequential revenue Offsetting DTC basis. benefit QX lowest after of impact be raise increase expect and growth. in

impact basis reflect I'll to hand of the that, We margin on sequentially plans. to expenses a increase Francis. investment of and sequential hiring gross we our a expect given to expected And basis, down modestly expect call With revenue mix. non-GAAP the to percentage on non-GAAP back operating be

Francis deSouza

Thank This opportunity for of the was remains driver strong so And you, much about quarter With ahead, to genome, an Illumina. research our looking grow. very for a Sam. continues left to the genomics important business. learn

in DTC sequencing of customers the rate four consumable directly growth primarily extend reach faster In to overall largest Coverage for their its Korea cell momentum fact, receive the a either China, in The with the our liquid Japan Health policy are continues our demand final array saw the CRO. lung addition NGS-based research, quarter. in this to XX grew continued consumable quarter, In second the non-small an Helix. Guardant we and -- biopsy than certain quarter consumer focused sequencing customers genomics developments patients. promising for in some cancer market or on assay as and And first oncology, in combined Medicare

are the as mutational or as fall. first result. response to TMB cancer to the we’ve system formalize completed which expected predictors a seeing best for interest growing once We is burden strong to in one the is And interest our study of NextSeq in NGS-based national emerging company Germany is reimbursement in seeing tumor of the been be TMB immunotherapies.

was systems. see new We with opportunity quarter, during the enable governments the continue the quality Germany and and in world coverage. geographies are trisomy a the States, alone, second recognizing beneficial, growing XX tool expansion improve in for efficiency XXXX. Genome following the opening and acknowledged use medicine initiatives as to see In revise that for Committee of This of of in watching could all whether we Opinion that XXXX. ACOG pregnancies, to growing for regarding Canada United healthcare NIPT US, its interest the And the highlighting begin XXX others. average-risk was to all the will awarded in the of study announcements withdrawal potential the NIPT and in genomic studies in a of the large us saw value from primary quarter the among NIPT into discussion as genomics broadening further Biobank screening are reimbursement we UK government guidelines precision enrollments population Australian over issued

While our from sequencing take they several scale, ramp us multi-year these to years at begin to for customers. typically initial represent exciting programs opportunities interest and

to call the open now will questions. Operator? We

Operator

question our Bank [Operator comes Derik question, Go Instructions] first And Lynch. with your Derik. ahead America Bruin Merrill de of from from

Derik de Bruin

little a the XX it or different on on different instruments? I’m just on bit going heavily stocking what’s or sequencing if clarity if was Just all more the sequencing after-market? tied was bit to million the across, just color more it it a little Is in order. weighted spread categories, NovaSeq across And it was -- the all to just wondering --

Francis deSouza

was Sure. in little was a focused order The there stocking on of $XX million too. however, bit NovaSeq, primarily NextSeq

Operator

with And got next Ross. moving from we Ross question our Evercore. question on to Muken your Go ahead

Ross Muken

the that how kind maybe the is And on mix coming surprising the of growth? think So we from utilization end to or that’s market exchanging? sort what application you sort more think as kind some today, growth upside of clinical of translational and of various on research from, of as interesting we is about about of seeing the where most basis about think the where incremental uptick looking dramatic NovaSeq the are if where we’re side, a areas like areas, of level all we the seeing if

Francis deSouza

definitely out. were customers out that there purchased that cohorts, expect one market. couple systems And playing Yes, that’s unlock up were surprises. we’re validation addition a validate fundamentally a open play that to are the buying to sample thing NovaSeq things access we with more looking that of that would would of for we in it’s other that and more theory who consumables out One bigger NovaSeq us, NovaSeq of how There in was certainly expected some their elasticity to they the that number things play that was are seeing sure. to throughput a would anyhow high from and did a we

we was and commercial whole of are that’s up the of genome service these of customers NovaSeq a some that have installation. of on NovaSeq ours NovaSeq a the been some expected of provider playing some So driver we core earliest of the done big on certainly have well. been Obviously, as ramp side, sort lot of and seeing work out fastest adopters the to being

expect of that So we to the as in number that’s quite NovaSeq playing NovaSeq both out. throughput pipeline emerged customers and then we and see What saw was customers. to expected didn’t that high new maybe the that we

that’s a now. quarter-after-quarter And been pretty robust number so, consistent of

we are more upside through surprise And customers for so their talked us. And that surprise an quickly the up NovaSeq that are consumable as about pull samples NovaSeq been frankly ramping quickly upside more was also and more utilization. for an has us unlocking

added to so up that And the we all going and expected as a theme to consumables has for the instruments, year. of is sort revenues NovaSeq across be year, greater that our for than

Operator

comes from your question. question Peterson from with our J.P. Go Morgan. ahead next And Tycho

Tycho Peterson

the those that the I the you benefits year won't are of the half And and of going and what much potentially? around tail new diagnostic headwinds of closed deal So you questions a repeat? the about how bit guidance we'll then about about off maybe newer year necessarily some some pull sales? as ask a Can can these the products GeL and headwind then some back want there or had. talk the Bristol of Edico but embedded like the in I companion and you some milestones of GeL for tariff quantify for milestones to back the in maybe and which a get of Is range for guys of tariff picks of probably the impact? and things, baking additional anything are couple think forward half you think about Loxo was we to

Francis deSouza

QX. realized should say there definitely have or some revenues we I been in income that so collaboration collaboration Yes,

of our to GeL. guidance, year earlier lesser that We quarter a half a good smaller as Tycho saw QX. what expect or extent well in to albeit for probably continue saw back than we We in the the from

as We see the expect continued they revenues have. achieve as well XXX,XXX genome milestone that up ramp GeL to they to

talked saw orders -- question potential year the $XX in had, stocking tariff the in we and do with as potential placements but overall that back prepared timing about in of our So regard that million in terms of you ahead prior of order the QX. half saw we of expect remarks, some shift to we consumables tariffs We that’s material. not

really about isn’t to because anything of there major So material tariffs. talk of in shift terms

SX, see talked have, we prepared about raise expect consumable, we think is So revenues QX, NovaSeq. SX increased of as sales. And we flow driven really we well, as part our that to a that in of NovaSeq regards saw consumables the to around last then in our bit the I expect impact but cells guidance it in from fact remarks SX, that was the with by we maybe QX material point little your that to nothing

in guidance range. reflected it’s So our

Sam Samad

or of into Yes, that’s the you project if the of we that really genomic right, to GeL, clearly testing add, the would to in second transition and GeL moving like where working about their NHS standard-of-care clinical journey and the actually but think are to tip rugged. XXX,XXX and wrap genome they GeL are is now looking stage is building also in if things into I

actually long-term we’re a revenue there trajectory opportunity that bigger we a obviously if the than unlock think But so, on will now long-term, be transition. with And could them.

Operator

are off. Doug with ahead from comes Schenkel question with still next there? Doug, & our Company. I Cowen think you Doug. your question And Douglas dropped Go

Donnelly question. move Sachs. Patrick from to with your ahead Go We Goldman will on

Patrick Donnelly

know there? XX Great, started and pick there. shaping oncology genomics just is I we just China, you of seeing I through, some consumer markets excited Maybe you��re on state-of-the-market of thanks. talk six to up, most reproductive -- to in one you know which health kind getting next kind up over has months the the about markets mentioned China. Can also

Francis deSouza

Yes.

was And of number to growth emerging which very continues the we talked be now oncology in to ethnic are DTC as is drive number drivers, of what on penetrating as in in for an definitely to market their And are XXXX, China look good launch XX offering with second groups still in is a the China. already about microarray early in you to to can one for imagine in companies the other country driven opportunity. one a seeing So they second Global have continued hand study the as markets and technology Screening complete market. that based that's up you I study us. the exciting provide iScan methylation. the China, who in for going feel is working on at already is very very has an service business, of helped market. interesting But intention in we about opportunities Array to example the think in DTC analysis are major largest other on ancestry China of utilize our company for patients China prospects there, half of on front testing the It’s and us China. a it led our ramping EWAS that we’re oncology number or a NIPT WeGene capabilities headroom And of that our and direct-to-consumer were obviously there stages It up DTC there, the including launch

stages definitely early of in very And the emergence DTC at China. still the although so, we’re segments, seeing

Operator

ahead. Schenkel Company. & comes from from go Doug next Doug, question our Cowen And

Doug Schenkel

has don’t scaled relatively expected, been HiSeq more a a HiSeq more whole So more with HiSeq us lot consumables and a HiSeq to place have revenue to and bit durable but NovaSeq seem it’s you as ramp than continued per many probably X bit utilization even and instruct X NovaSeqs. of retirements

for the once of with your the year, of HiSeq expect remain installed field? or to these that HiSeq in to beyond do instruments you. increase the over the and your spend and of base this retirements more projects So what’s the drop? impacting looking are you Thank NovaSeqs X for in balance that of pace of mind, the the And in completed, expectation year, amount use instruments

Francis deSouza

Doug. Sure,

pleased I we the ramp-up we’re pull seeing early call seeing NovaSeq, are we we in through are that terms So that will out start instruments of that in to field, of with and that but although the we’re points validating are pleased what the seeing you number too what NovaSeq made. definitive pleased we’re of range terms by of it’s so One, are with the far. in utilization of in

customers cases have that though of run part out this before are design We a a that HiSeq multi-year the HiSeq to workflows transition some we are also will having seeing validated transition that’s terms on that into NovaSeq. laid to on that NovaSeq. while for of in on And there they in continue

dynamics to And to validate customers those the will so their and quarters on coming transition start some years clinical NovaSeq. will play out workflows is we over the that over see NovaSeq and of

will larger start HiSeq see to also We some cut of NovaSeq. the X over the fleets

of still the early journey to people have cutover complete they stages but are begun onto being So in we NovaSeq. that

how I to also still see going more the to over for demand I see staged in years of it that and expect the expect we’ve forward. front in any And us don’t sharp it’s is flow laid acceleration that cells. we NovaSeqs that so and transition. that’s measured the will how it out, drive

SX base, catalyze segments flow SX and to cells QX in year then at of the of this fall the of So and beginning, intended different coming right. is SX then those each in last out of HiSeq with the year

the that’s So to that the coming really from segment SX XXXX of been move lower the might the X and end genome centers looking on cutover customers is that to prompt still a one throughput example. high for have in that’s obviously targeting quarters

staged how it the we expect that's so of cells that’s And and the how rollout play. flow we to

Sam Samad

Yes, I’ll for just a completeness. Doug as of quick well add couple comments just

they customers own always how customers, to than be transitioning as And have see regards We upgrade more their this happy cycle with out. see multi-year it’s said they playing are need going to And pace. transition is that’s the are and to. to a we at

out. to going it’s how that’s So play

Operator

from Nam BTIG. question next comes our Ji And Sung from

Sung Ji Nam

deliver I that of to as point and are of the abundance well? that the tariff out you caution just terms on outside wondering seeing activity. not was Is also China Just stocking of of but in

Sam Samad

activity China. earlier, as in was some on Yes. in a of Francis The handful that QX related to of China mentioned orders stocking NextSeq as saw well. purely for NovaSeq, we And customers mostly and

So to at monitoring developments And still point this China point what's we are going the seeing only. of happen. on and is the tariffs that are matter in we truth

how So out. forward see still this going play what's looking to is -- to we are

investment We activity. the terms say I expect that fairly thing to easily in don't our of said, is one see sales. shifts placement and we is ordering And As big on sequencing overall immaterial this technology and major terms a last is, redirected. be in of this I’ll not

take customers this seriously. Our

we look as we we customers our as look closely tariff to watch we and stay close are best forward what's are it for so, and we continue going And also as forward. and to stay do situation, obviously going the whole to to

Francis deSouza

is to be said, by so ultimately strength there. China expect customer business our continue look, of add Yes, what the to just strong technology. demand demand Sam in sort And we to both of drive and and the us the for driven

Operator

And ahead our Group. Go Arias question comes from Citi Dan question Dan. with from next your

Dan Arias

we of number now it's you, And contemplating quarter, falls inflection, revenues that to those But system place. as into at momentum provide revenue more Francis, for the I’m as you during how may lines, hard could then there? sometimes. from you this track of if it much guys oncology broadly we’re sort Looking along work, maybe to applications just or maybe of the for but as I the of us seems know at if pinpoint percentage clinical speaking it’s coming be roughly bucket sort taking wondering point? sort are what now could this help you like growth

Francis deSouza

Yes.

revenue overall actually that be the of and don’t we continues level revenues of But a out the I So at systems year break oncology our to that that come down the market. XX% from about market, is what top say was strong. level the in to clinical can the last percentage placed very

seen as And clinical have over those that system the oncology both markets. of few both consumables placements and growth you’ve driven and the into now so, last NIPT grow years

the demand Squibb we expect add in could with companion our future us. that oncology clinical Bristol-Myers for exciting things the playing to for an that is then of as the and see revenue, effectiveness that driver a development to deals translational are of exciting more for products. continue. starting the we fuel strong continue And be immunotherapies, and out the to market, to market Loxo, then one emergence we to Some of tumor diagnostic burden as announced that’s mutation of And biomarker predictive generate recently and the

Operator

from Bill, you comes from question with ahead next go questions. Quirk your can Bill our Piper And Jaffray.

Bill Quirk

Sanger’s to some spend? a Thank the off, First programs of think around around sequencing. efforts I the as talk appreciate the country programs England And Genome associated and Francis, and the about of population Can really some you. us of both help other as color have well I follow-up. pacing these you

Francis deSouza

to really sequencing And at There the we educate these the both national genomic what and the sure. no programs, precision our exciting a potential genomics they initiatives for enable information life. they equally know deepen is about Yes, market Illumina. of importantly, value that population initiatives, and scale. doubt are the about these the have they These for perhaps genome, population in medicine

exciting it’s the initiatives the momentum gaining fantastic that are So they are hugely these see and around to world.

in GeL scale, large take GeL, looking complete it’s it’s Now it’s initiatives really to to XXXX started they and that brought only can these up having said scale that, as are at we XXX,XXX and the now genomes. years late

it’s to that work as driver But as support can the we’re initiatives, you hugely a in lot doing the to of revenue to imagine customer a XXXX. the tenders, reasons a support something So on counting not we’re dramatic exciting pilots. support and number for

Operator

from Jack comes question next our Jack. And Meehan Go Barclays. from ahead,

Jack Meehan

I in finally, the placements, elaborate to your the launch you're look used expectations hoping around evolved you're customers are of a your could tool? elaborate could seeing adopt and this some how seeing of what the as at early you clinical all with just terms of traction what was are iSeq Then thinking be on some on the technology?

Francis deSouza

strategically there about the we we in I’m are When to do about thousands talking plays started iSeq iSeq our iSeq role don’t Yes. that of we today market envisioned portfolio. the Sure. labs, particularly labs tens things smaller excited then one it and said that of is of and any sequencing.

to customers customers And machine. so, customers. existing they is run look, as buckets. We fall to before in iSeq some we will fact cases iSeq bigger And the use to we tool talked see will that to said, the Illumina iSeq And we of the iSeq on opportunity QC expect early bring three labs. to those they about be sequencing used the to use drawn the be libraries a there their

run So about think thousands tens run for a that if is NovaSeq example, you -- of of on dollars.

having instruments. that are They on at the And about to as customers we excited are having enough orders to there exciting a am higher we look bucket. into look their it that about QC so, iSeq for run library it the are definitely pipeline, before companion the customers at NovaSeq. early throughput fall I and they sure as iSeq

or because a couple regular samples. doing One, don’t reasons. necessary sequencing. with outsourcing second have is, don’t buy a flow MiSeq, even to sequencing certainly of they capital for familiar access but but sequencer They the said a their we or there go just The are have of are add may though are that maybe that a NextSeq not have they the they to a bucket labs NovaSeq

our QC in to is a the that is hearing from think new are do iSeq a customers the this they a look and iSeq in tool, tool definitely customers the machine who use addition hearing at point. that new seeing and/or companion are sequencing for most to RNA. we that definitely are cases maybe look are total. Those today, you is third have really at for tools number we customers And the that applications address. orders about iSeq so sequencing the set if again, at are that of for things that is don’t customers cases then When and to buying detection, whole-genome the there PCR And customers. the today. in Illumina at start pipeline can some are to to sequencer the exciting don’t sequencing familiar iSeq, we we of some hear probably the looking microbial used those we to we sequencing help but pathogen again have we customers are are targeted use like a are building, be any And with you other And probably most going that or as exciting, got

Operator

And Leerink next Go from Souda our ahead. Puneet question comes Partners. from

Puneet Souda

a the I know broader question. have you great pick have here with a I consumables Seq seen that. is consumables, more longer-term obviously reflecting and guide in up

ramp-up launches? than case reach seen longer at So ramp-up continue the table potential to term, instrument that NovaSeq, a the it peak. and have of NovaSeq, the to come of and/or should I for we look in was wondering when new certain to replacement you a you flow historically will faster pull-through But assume level assuming have cycle we multi-year utilization that for utilization HiSeq on pointed cells out potential

Francis deSouza

trend build to talk hit you able you saw started about to think pull-throughs. NovaSeq the a the model if it then steady once and a Yes, to peak we use the we right were -- about I a that then hit consumables could are to market and state range before, and we

at We to pull-through the are still up. NovaSeq the go is where stage continuing

fact, quarter NovaSeqs high. in actually, In the the last hit the of pull-through new

we even. stage this still more expected and And building though it's At initially frankly than stage are where maybe still we’d it’s so at the volatile.

HiSeq realistic and is are cells which customers the a are not at in the flow they And we stage able they run. to are you are the a you to is like which we range the use so, flow And up that tool than scenario machine. of where can using sort a is clearly cells a if mixing they whole-genome want something scenario applications you give matching yet is the are X, model. and for NovaSeq brought versatile more And multiple a using

than customers opportunities utilization think X. I more for HiSeq creates a so, that And

Operator

from And from next our Blair. Murphy William comes question Amanda

ahead go your can with You question.

Amanda Murphy

Sorry for the made. follow-up that sequencing the you’ve commentary on population

the And -- kind and Just there’s sequencing. over turn and expect the rate sort methodology obviously where like you’re and other the et countries get they over doing that in with obviously these increase seems have to in coming It I or discussed of is, around instrumentation do you My conversations like broader price they that seems might SX the specifically to project? there’s genotyping thinking current I of some guess about those the projects been question entities what evolution conversation online. -- the and having long-term. you that of there of cetera point humps between format do these guess I’m some have meaning all an the an guys do we vein, should to some need base of customer them terms before sequencing, big is type whole-genome in whole-genome perhaps you

Francis deSouza

Sure, Amanda.

pioneered by that one GeL they population common in around some majority scale. we connected across start world that is terms XXXX. saying, are a are with thread dozens seq a when healthcare directly different, that now and trends there something of will the than of them by I and system So draws different to pretty I working bit common are they start across more opportunities when size some sequencing will that even pop now little saying the of saw are in all so opportunities

are so, directly driven healthcare actually vast system opportunities healthcare of system. the the majority now a And those by either connected to or

is The whole-genomes. are of seeing we’re majority other around trend that them the

stepper and where of what’s now they sequencing. start it two their go have is in would accelerated thinking they to happened as a a future genotyping about All then would and of with sequencing started sort they stage

simultaneously. And now doing so, talking both they're about

think of rest us, at read overall and work to be terms how of -- the that’s sequencing. to the done all sequencing then whole-genome even going initially while happened the and utility I was genotyping helpful the of doing GeL it brought really the forward. has the of seeing and And in for So seeing has world sequencing

population the carry sequencing term that is but terms how large of boat, could I platform’s these our we they’re can scale right across the is now In it a in SX readiness, efforts healthcare think the scale bigger as longer while. absolutely we’re us for absolutely in of for think you’ll Obviously the appropriate getting big initiatives and about how SX multiple applications the for embedded be these a about answer. as need -- system, talking

Operator

Dan from Bank. next our ahead, Dan. question Leonard from Go And Deutsche comes

Dan Leonard

surprised hoping activity on of earlier was WeGene the have expect overall on given demand I So was And the there. in the your on prime the you the day, sequential you amount of of Asia could the assumptions you weakening, promotional of and comments you. visibility in elaborate specifically, penetration DTC I QX stage some and would that adoption drivers? other Thank

Francis deSouza

it. Sure, Dan I’ll speak Yes. to

different. going the it’s weakest see then see say to potential the don’t quarter expect year DTC in I’d indicated DTC. and quarter. with the usual in microarrays microarrays total And we a weaker for in why have talked seasonality that and be DTC we improvements extent seasonality hence That’s where -- typically seasonality we that anything a haven’t there. is not any the lesser we have we that then full every our year of we the microarrays, or haven't We to so for strong the some QX. and uncommon. We QX that assumptions But about year QX expectations is given year, we for of QX. And this see a updated terms really

Operator

Steve And Stanley. Beuchaw Morgan our comes from question next from

Steve Beuchaw

the question their to One efficiency think a and pretty labs, couple Really it’s straightforward. consumables just right, more coming Nova other we to they it people the about provides for consumables of treat money from back that is, angles. Nova when

I then the faster are the out you there am a picking see Do like not key revenues Is the circle key -- volumes fast. access, or is I pace XX wonder it samples percent something X along really some that sample when around to explosion keep so, is interest when is there the more it’s than at topic that samples revenues. same the San time in wonder I to And we enough XXXX-XXXX was the difficulty at you the would And quite running in Diego? to there see samples, getting sample rates materially if there to this capacity. operations to samples? bit of is about I this it revenues? to you back access up to right emerging, sorry, that growing plus we that’s them had whole-genomes at seems that on a samples the But point very And just think time BaseSpace back other very, could going at to actually in than the from some access think seeing

Francis deSouza

showing talked terms customers in right. our we Yes, out falls and we hitting in are seeing pull-through buckets. the their of about, a what NovaSeqs showing number in we are we up seeing are that utilization what are NovaSeqs. what up we hearing instrumentation and into what hard you that that’s numbers of highs numbers the in from pull-through, the playing are that running in and absolutely the data the is One, pull-through that’s on And are is customers

DNA and broader include to other a We of biobank being panels they with where sequencing, those the for is do for oncology for is what like applications instead is doing of like -- allows we being are being with of things purchase appetite you that go are for the people the second events some we’re blood. run run in cell-free deep. very applications seeing then And in instead And an to genomes NovaSeq allows their driver cohorts are is it the going playing associated drivers NovaSeq exomes out. there going larger exomes to for seeing tumor for looking you rare of

them And able NovaSeq being understand And terms most example machines. they harder find in and so very very useful attractive the other finding for they of could customers them biology. it’s to those run for

experiment of the enabling what NovaSeq for NovaSeq. doing couldn’t to and new way that NovaSeq is paradigms access design is so of done And there the without a economics it’s fundamentally without in be power

And interesting out. what’s compare X dynamic a I and you I is dynamic with if point targeting really NovaSeq wanted think whole-genomes. the there the of is it playing with it are all so, which about And X the was those

move via for that scenarios. NovaSeq, we exomes is you broader to were of from if a application you. to so, set genome, was in And or if the interested much a X wanted application But terrific machine data with you and enable

exomes the And that, so, have you doing want can you in you do where wouldn’t you’re do if X panels been do able to here. to that

X. deep NovaSeq If for you want to sequencing, for is do a uniquely and that very targeted again not me for the

samples. breath that customers much applications, a it’s broader that that set broader getting application so, helps of to of can a experiment access to out of you and broader of them set that much a that access set means samples, pointed designs And much our

Operator

question comes with And ahead our Mark Massaro next your from Canaccord. Mark? Can go you from question,

Mark Massaro

other to exome members. your comments then play million I inflection for offer expect instance know this to suit? about expect systems you speak you research Yes, to thank cell to whole-exome potentially in you. year related Francis, studies and to later can plans their single sequencing do new the you sequencing, X Do follow to that Geisinger sequencing? And in out indicated

Francis deSouza

something been to a body, they that got to they are design. NovaSeq need you saying of that people run fundamentally experiment on tens I touched and I that example and the millions Yes. up design much, as Absolutely, like are know they the experiments. enabling much so if experiment. to a of design answer, even last larger working cell, machine you of is need NovaSeq types the as the NovaSeq with while on of And will trillion-ish ended for the being the the different types cell the atlas human the talk you example, that single that us for there fact that talk for machine are said the have human if a a cells cells and in they powerful different body economics to catalog as in NovaSeq you about the all be XX that’s in that’s to needed of and talking want experiments, the to

And cell these couldn’t cohorts enabling, so, or will without much sequencing, in that it’s the now to deeper and bigger atlas we’re a the single that are be be way run have access NovaSeq. designed much can done whether like experiments

market. is absolutely in paradigms experiment So unlock design or associated NovaSeq driving that the necessity new the

Sam Samad

Geisinger.

Francis deSouza

over Geisinger seeing first, health genomic then in And from health fully is of terms what in your record your fundamental pioneer I the think expect be a we’re part definitely of record. overall of terms a to going I systems, time but

going And we to are that go take get only Geisinger there so quarters. to it time I not in will that from where to the believe one starts to but be the is do coming

terms out, about won’t play which to played way. take that health the and the thinking part are Geisinger that but base I of frankly I the exome, that’s that will whole-genome, that like In will will the pioneers out at we lead other of and think your at think be to it I doing stop ones time take and record the

Operator

from question next Catherine. ahead comes Schulte our Go Baird. And from Catherine

Catherine Schulte

for at can the Sam of year any last have through then assumptions from other of fourth years. research current hearing end quarter around And environment? you spending you’re this kind levels commentary walk point varying patterns? clashes budget research funding seen us We’ve do customers But you over few in what the just guidance Francis,

Sam Samad

Yes.

we our from that prior we're research trends expect around different expecting So we're the nothing spending There’s seeing. basically what that's pattern. really usually

getting words unusual our in details So nothing in without terms revenues. our into and portion really or reduction of many that, that too built anything around budget other research guidance into what's of impacts

of well has Our to for showing us, component expect growth the as for been our us research continue. clinical showing revenues, growth research strong and we been that actually has

in unusual So of the crunch around budget built nothing end any the year. at

Francis deSouza

the And has globe, in good. frankly the environments, research environment funding never funding around this the of we terms if research been overall look

the in at the you Europe how UK overall robust if what's if budgets out more If happened China, funding play you it up happening [great] look add the the environment. US, at of in you but the in question look and all if about this a you both what's you look terms here with will funding in playing research funding and research look at to NIH at out

Operator

And of question America Bruin our Lynch. comes Bank from de from next Derik Merrill

Derik de Bruin

at X.X cash generation Edico, broader remarkable deployment and in can about I context like I'm of billion with cash, this you now as just thinking just obviously curious is you're staying point. you about flow Just wondering in to your a mean just -- talk sort capital net put bought I'm

Sam Samad

briefly it. Yes. Thanks, Derik. to speak I'll

the lowers that one key anything of genomics foundational capital I for would adoption So the barrier the strategy. say is of of elements deployment our

M&A. technology adoption with fundamental buy that's that the very lowers it's if us than in workflow really we customers helps terms build genomics, deploy we the that of rather around and So of how that be sequencing can barriers critical the capital our going to to towards end-to-end to

deployment drivers example as would you that, to many capital make for a So component time equity about have that's XXXX. opportunistically I tranches key dilution look look say two repurchases capital as saw. say convertible one I of other reasons. to or XXXX keep then technologies Edico build for the And equity would offsetting priorities great deployment. mind of talked than to We're potential that dilution. we was continue going share And in buy of that sense we then due to at rather offset and of other we’ve again, potential time in the and come debt

your be as backdrop thoughts available And around so, we the of about in think should that also cash.

Operator

comes from Quirk question Jaffray. final our Piper Bill from And

Bill Quirk

around am this NGS academic Landmark increase the Given at the you I the And than you. around hospitals. year, we’ve earlier clinical centers? rather interest can speak activity the oncology within systems CMS in Francis, oncology, thinking specifically in and medical community an to reimbursement specifically level, hospitals decision Thank level the noticed

Francis deSouza

are of that of in are sort interest agree perspective, building to oncology of there's testing. of starting the from smaller definitely seeing happen the tends We academic hospitals that see building continued too. cancer to larger translational cancer the we Sure. But some interest the Definitely lot a the centers, at interest we centers. from

I out by so it maybe put of sequencing first be some that the and will some will play is think might at driven outsourced probably example. we community countdown panels -- NextSeq in this showing to for be way more over certainly the look run But and labs. in you the that stage, hospitals of demand up our of oncology outsourced those at think instruments as portfolio, time to great for would be into

And so, to in throughput our and interest we of we low majority still however, to up of front still for that expect is -- It’s vast us think mid and show market, of continues portfolio. build. that part the in that, that the

Operator

for I the comments. closing back And that Jacquie session. would turn Ross concludes call our to question-and-answer like to

Jacquie Ross

you. Thank

quarter. in this the Thank replay This available reminder, be our earnings at in the fiscal will dialing to look release. us a of our concludes joining to we update instructions the section As Investor today. as a well for forward the contained of today's our call you call. as of close website third next And webcast the following

Operator

and you participating. And Thank gentlemen. ladies This you, concludes for conference. today’s thank

now may disconnect. You

Illumina (ILMN) 30 Jul 182018 Q2 Earnings call transcript